Product image of Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone, Luteinising Hormone, the active ingredients in Meriofert, are gonadotropins presented as a sterile injectable solution for subcutaneous use. They are employed to stimulate ovarian follicular development and ovulation in women with specific reproductive disorders.

GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers receive dedicated technical support and assurance of product integrity throughout the supply chain.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert, a gonadotropin preparation, is used in reproductive medicine to address disorders of ovarian function.

  • Infertility due to anovulation: promotes follicular growth and ovulation in women who do not ovulate spontaneously.
  • Controlled ovarian stimulation for assisted reproductive technologies: enhances multiple follicle development to increase oocyte yield for IVF or ICSI cycles.
  • Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal ovarian activity.

How It Works

  • The FSH and LH components of Meriofert bind to their respective receptors on ovarian granulosa and theca cells. FSH activation stimulates granulosa cell proliferation, aromatase activity and estrogen synthesis, while LH triggers theca cell androgen production and final follicular maturation, culminating in ovulation. By mimicking natural gonadotropin signaling, the drug restores the endocrine cascade required for follicular development and oocyte release.

Side Effects

Meriofert may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild discomfort or tenderness at the subcutaneous injection site.
  • Headache: transient headache occurring shortly after administration.
  • Nausea: mild nausea that usually resolves without intervention.
  • Ovarian hyperstimulation symptoms: abdominal bloating, mild pelvic discomfort.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement, fluid shift, and risk of thromboembolism.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Allergic reactions: rash, urticaria, or anaphylaxis.

Precautions & Warnings

Prior to initiating Meriofert therapy, clinicians should consider several safety precautions to minimize risks.

  • Assess baseline ovarian reserve: evaluate antral follicle count and anti‑Müllerian hormone levels.
  • Monitor estradiol levels: frequent serum estradiol measurements to detect excessive response.
  • Screen for contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or malignancy.
  • Counsel on OHSS risk: educate patients about symptoms of ovarian hyperstimulation syndrome.
  • Review concomitant medications: consider potential interactions with estrogen‑containing products.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert can interact with other agents that influence ovarian response or hormone metabolism.

Major Interactions (Avoid)

  • Exogenous estrogen therapy: may exacerbate ovarian hyperstimulation.
  • Aromatase inhibitors: can blunt the intended estrogen rise and reduce efficacy.

Moderate Interactions (Monitor Closely)

  • Gonadotropin‑releasing hormone (GnRH) analogues: may require dose adjustments.
  • Anticoagulants: increased risk of thromboembolic complications if OHSS develops.
  • Thyroid hormone replacement: monitor thyroid function as hormonal changes may affect dosing.

Frequently Asked Questions

Meriofert is a gonadotropin preparation indicated for infertility caused by anovulation, for controlled ovarian stimulation in assisted reproductive technology cycles, and for treating hypogonadotropic hypogonadism where endogenous FSH and LH are deficient.

The FSH component binds to receptors on granulosa cells, stimulating their proliferation and estrogen production, while the LH component activates theca cells to produce androgens and supports final follicle maturation. Together they replicate the natural hormonal cascade that leads to ovulation.

The dose of Meriofert is individualized and set by the prescribing physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol being used.

Meriofert is intended for use before conception to induce ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it should only be used under the guidance of a qualified reproductive specialist.

To order Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meriofert contains both FSH and LH activity in a single formulation, similar to other combined gonadotropin preparations. Compared with recombinant FSH alone, it provides additional LH support, which may be advantageous in certain stimulation protocols, while offering comparable efficacy and safety when used as directed.

Meriofert must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any vial that has been left at room temperature for longer than the period specified in the label.

Meriofert is administered by subcutaneous injection, typically into the abdominal wall or thigh. The preparation is supplied as a sterile solution that may require reconstitution according to the manufacturer’s instructions before injection.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can lead to severe fluid shifts and thromboembolic events, as well as rare but potentially life‑threatening allergic reactions such as anaphylaxis.

Meriofert is contraindicated in patients with active ovarian cysts, uncontrolled thyroid disease, known hypersensitivity to any component of the product, or those with a history of severe OHSS. It should also be avoided in individuals with malignancies that are hormone‑sensitive.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT